From: Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
ClinicalTrials.gov Identifier | Responsible party | Ph | Drugs |
---|---|---|---|
NCT01033292 | Sanofi | II | CBDC/GEM with INI in Pts with platinum-resistant recurrent EOC |
NCT01033123 | Sanofi | II | CBDC/GEM with INI in Pts with platinum-sensitive recurrent EOC |
NCT00677079 | Sanofi | II | INI in Pts with BRCA-1 or BRCA-2 associated advanced EOC |
NCT01482715 | Clovis Oncology, Inc. | II | RUC in Pts with gBRCA Mutation EOC |
NCT01891344 | Clovis Oncology, Inc. | II | RUC in Pts with platinum-sensitive, relapsed, HGSOC (ARIEL2) |
NCT01968213 | Clovis Oncology, Inc. | III | RUC as switch maintenance after platinum in relapsed HGSOC (ARIEL3) |
NCT00664781 | Cancer Research UK | II | RUC in known carriers of a BRCA 1 or BRCA 2 mutation with advanced EOC |
NCT01690598 | Vejle Hospital | II | VEL and TOP for Pts with platinum-resistant or partially platinum-sensitive relapse of EOC with negative or unknown BRCA status |
NCT01472783 | Vejle Hospital | II | VEL for Pts with BRCA germline mutation and platinum-resistant or partially platinum-sensitive relapse of EOC |
NCT01113957 | AbbVie (Abbott) | II | VEL with TEM vs PLD alone in subjects with recurrent HGSOC |
NCT01306032 | National Cancer Institute | II | VEL in combination with metronomic oral CYC in refractory BRCA-positive EOC |
NCT02470585 | AbbVie | III | CBDC/P with or without concurrent and continuation maintenance VEL in subjects with previously untreated stages III or IV HGSOC |
NCT01540565 | National Cancer Institute | II | VEL in persistent or recurrent EOC with germline BRCA1/BRCA2 mutation |
NCT02392676 | AstraZeneca | III | PLA controlled study of OLA maintenance in Pts With platinum sensitive relapsed EOC and loss of function somatic BRCA mutation(s) or loss of function mutation(s) in tumour homologous recombination repair-associated genes |
NCT01874353 | AstraZeneca | III | PLA controlled study of OLA maintenance in platinum sensitive relapsed BRCA mutated EOC Pts with a complete or partial response following platinum based CT |
NCT02571725 | New Mexico Cancer Care Alliance | II | Combination of OLA and TREM, in BRCA1 and BRCA2 mutation carriers with recurrent EOC |
NCT01844986 | AstraZeneca | III | OLA maintenance in Pts With BRCA mutated advanced EOC following first line platinum based CT |
NCT01081951 | AstraZeneca | III | OLA With P and CBDC vs P and CBDC alone in Pts with platinum sensitive advanced EOC |
NCT02503436 | AstraZeneca | II | OLA treated BRCAm EOC POPULATION |
NCT02282020 | AstraZeneca | III | OLA vs Physician’s choice single agent CT for platinum sensitive relapsed EOC in Pts carrying germline BRCA1/2 mutations |
NCT02484404 | National Institutes of Health Clinical Center (National Cancer Institute) | II | Anti-programmed death ligand-1 antibody MEDI4736 in combination With OLA or CED for advanced solid tumors and advanced or recurrent EOC |
NCT02340611 | University Health Network, Toronto | II | Combination CED-OLA at the time of disease progression on OLA in EOC |
NCT01661868 | Ursula A. Matulonis, MD, Dana-Farber Cancer Institute | II | OLA for Pts with recurrent BRCA deficient EOC with no prior PARP exposure or prior PARP inhibitor exposure |
NCT02477644 | ARCAGY/GINECO GROUP | III | OLA or PLA in with platinum-taxane and BV and as maintenance therapy |
NCT02345265 | National Cancer Institute | II | OLA and CED for the treatment of recurrent EOC |
NCT02208375 | M.D. Anderson Cancer Center | II | OLA With AZD2014 or AZD5363 for recurrent endometrial, triple negative breast, and ovarian, primary peritoneal, or fallopian tube cancer |
NCT02502266 | National Cancer Institute | II/III | CED and OLA compared to CED or OLA alone, or standard of care CT in women with recurrent platinum-resistant or -refractory EOC |
NCT02489006 | University Health Network, Toronto | II | OLA in Pts with platinum sensitive recurrent HGSOC |
NCT00628251 | AstraZeneca | II | OLA vs intravenous liposomal doxorubicin given monthly in Pts with advanced BRCA1- or BRCA2-associated EOC who have failed previous platinum-based CT |
NCT02485990 | Sidney Kimmel Comprehensive Cancer Center | II | TREM alone or combined with OLA for recurrent or persistent EOC |
NCT01116648 | National Cancer Institute | II | CED and OLA for recurrent papillary-serous ovarian, fallopian tube, or peritoneal cancer or for treatment of recurrent TNBC |
NCT01078662 | AstraZeneca | II | OLA in Pts with advanced cancers BRCA 1 and/or BRCA2 mutation |
NCT00494442 | AstraZeneca | II | OLA twice daily in Pts with advanced BRCA1 or BRCA2 associated EOC |
NCT00679783 | AstraZeneca | II | OLA in Pts with known BRCA or recurrent HGSOC and in known BRCA or TNBC |
NCT00753545 | AstraZeneca | II | OLA Pts with platinum sensitive relapsed serous EOC following treatment with two or more platinum containing regimens |
NCT02326844 | National Institutes of Health Clinical Center (National Cancer Institute) | II | TAL in Pts with deleterious BRCA1/2 mutation-associated EOC who have had prior PARP inhibitor treatment |
NCT01989546 | National Cancer Institute | II | TAL in Pts with advanced solid tumors and deleterious BRCA mutations |
NCT01847274 | Tesaro, Inc. | III | Maintenance with NIR vs PLA in Pts with platinum sensitive EOC |
NCT02354131 | Nordic Society for Gynaecologic Oncology | II | NIR and/or NIR-BV combination against BV alone in HRD platinum-sensitive EOC |
NCT02354586 | Tesaro, Inc. | II | NIR in women with advanced, relapsed, HGSOC, fallopian tube, or primary peritoneal cancer who have received at least three previous CT regimens |
NCT02657889 | Tesaro, Inc. | II | NIR With PEM in Pts with advanced TNBC and in Pts with recurrent EOC |
NCT02655016 | Tesaro, Inc. | III | NIR maintenance in Pts With HRD-positive advanced EOC following response on front-line platinum-based CT |
NCT02446600 | National Cancer Institute | III | Comparing OLA or CED and OLA to standard platinum-based CT in women with recurrent platinum-sensitive EOC |
NCT01434316 | National Cancer Institute | I | VEL and DIN given together with or without CBDC |
CRUK/13/023 | Cancer Research UK | III | OLA with CED vs CED and PLA as maintenance therapy following platinum-based CT with CED |